olanzapine and Osteoporosis

The etiopathogenesis, risk factors and indications for prevention and treatment of osteoporosis in patients with schizophrenia are presented. Accelerated decrease in bone mineral density (BMD) is mostly attributed to antypsychotics (drug-induced hyperprolactinemia and decrease in levels of estrogen and testosterone), insufficient calcium intake, low physical activity and limited exposure to sunshine, alcohol and tobacco intake, polidypsia. Clinical symptoms of osteoporosis (eg. vertebral fractures) develop very slowly and in patients with schizophrenia are very rarely diagnosed. Many of risk factors (especially adequate choice of pharamcotherapy and monitoring of BMD) might be prevented in order to decrease the prevalence of osteoporosis in population of patients with schizophrenia.

Topics: Antipsychotic Agents; Benzodiazepines; Bone Density; Comorbidity; Female; Humans; Male; Olanzapine; Osteoporosis; Prevalence; Risk Factors; Schizophrenia

The hyperprolactinemia induced by conventional antipsychotics often leads to osteoporosis. The commonly used atypical antipsychotics risperidone and olanzapine vary in their hyperprolactinemic properties. Therefore, we compared hormone profiles and bone properties in female premenopausal schizophrenia patients treated with either risperidone or olanzapine.. In a cross-sectional study, consecutive premenopausal, female, DSM-IV schizophrenia patients who were treated with either risperidone (N = 12) or olanzapine (N = 14) for at least 2 years were included. Dual energy X-ray absorptiometry evaluated bone mineral density, and multisite quantitative ultrasound measured bone speed of sound. In addition, profiles of urinary excretion of deoxypyridinoline and circulating levels of hormones and lipids were assessed.. Serum prolactin levels were higher in the risperidone-treated group as compared with the olanzapine subjects (123 +/- 144 and 25.9 +/- 25.7, p <.05). Whereas bone mineral density was similar in the treatment groups, bone speed of sound was lower in the risperidone group as compared with the olanzapine-treated group. Expressed as age-adjusted Z score, bone speed of sound at the radius was -0.31 and 0.58, respectively, p <.05, and at the phalanx, -1.41 and 0.04, respectively, p <.05. The bone speed of sound in the risperidone-treated patients inversely correlated with urinary deoxypyridinoline excretion (r = 0.73, p <.05).. Risperidone treatment, as opposed to olanzapine, for female premenopausal schizophrenia results in hyperprolactinemia and clinically relevant decrease in bone mineral density. The calculated relative risk for fragility fracture of women treated with risperidone as compared to those treated with olanzapine is 1.78 when bone speed of sound was measured at the phalanx and 1.23 when measured at the radius.

Topics: Absorptiometry, Photon; Adolescent; Adult; Benzodiazepines; Bone Density; Female; Humans; Middle Aged; Olanzapine; Osteoporosis; Pirenzepine; Premenopause; Prolactin; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists